At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 249 enrolled
Drug / intervention
AG-920 +1 moredrug
Likely dose
AG-920 Sterile Topical Ophthalmic SolutionAI-extracted
Key inclusion· 5
- ✓Male or non-pregnant, non-lactating female
- ✓Healthy by clinical assessment including ocular examination
- ✓Best corrected visual acuity (BCVA) of 20/200 or better in both eyes
- ✓Intraocular pressure (IOP) between 7 and 30 mmHg
Key exclusion· 11
- ✕Contraindication to local anesthetics, Septocaine, or any component of the investigational medicinal product
- ✕Ocular surgery or general surgery in either eye within the past 90 days
- ✕Intravitreal injection in either eye within 14 days of randomization
- ✕Ocular surface disease requiring punctal plugs
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Evaluation of the Ocular Safety of Articaine Sterile Topical Ophthalmic Solution
In Brief
A Phase 3 clinical trial evaluating AG-920 and Placebo for Anesthesia, Local. Completed, enrolled 249 participants across 2 sites.
Detailed Summary
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia, Local
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedAug 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedAug 16, 2022
Enrollment StartJul 30, 2022
Primary CompletionDec 7, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.9 years ago
Interventions
AG-920drug
AG-920 Sterile Topical Ophthalmic Solution
Placebodrug
Placebo Sterile Topical Ophthalmic Solution